Telix Pharmaceuticals Ltd 2021 SR
The report highlights Telix's commitment to ESG standards, focusing on patient safety, diversity, and environmental responsibility. In 2021, the company conducted its first comprehensive materiality assessment, identifying 14 high-priority topics. Key achievements include decommissioning legacy cyclotrons at the Seneffe facility and reaching an 86% employee engagement score. Telix also set measurable diversity targets, aiming for 30% female board representation by 2022, and reported that 43% of its global workforce is female.
Company: Telix Pharmaceuticals Ltd
Sector: Health Care
Country: Australia
Year: 2021
Type: SR
Pages: 5
Telix Pharmaceuticals Ltd
ESG Report
The report highlights Telix's commitment to ESG standards, focusing on patient safety, diversity, and environmental responsibility. In 2021, the company conducted its first comprehensive materiality assessment, identifying 14 high-priority topics. Key achievements include decommissioning legacy cyclotrons at the Seneffe facility and reaching an 86% employee engagement score. Telix also set measurable diversity targets, aiming for 30% female board representation by 2022, and reported that 43% of its global workforce is female.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2021
Reporting Period
Jan 1, 2021 - Dec 31, 2021
Fiscal Year
2021
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
Other Standards
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Women on Board
Women in Management